Penn Medicine Provider
Cardiology
Payman Zamani, MD, MTR
4.9
(48)
Accepting new patients
Sees patients age 18 and up
Penn Heart and Vascular Center

About me

  • Assistant Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Harvard Medical School
  • Residency: Massachusetts General Hospital/Brigham and Women’s Hospital
  • Fellowship: UC San Diego Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

48 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
easy to talk to, answers questions thoroughly, explains everything
April 2025
5.0
5.0
very knowledgeable, thorough and kind
March 2025
5.0
5.0
saved my life.
January 2025
5.0
5.0
zamani is all one could want in a doctor.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Zamani is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Saw EL, Werner LD, Cooper H, Pimental DR, Zamani P, Chirinos JA, Valero-Muñoz M, Sam F. Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction , Circ Heart Fail, Epub: 2025,e012350


Selvaraj S, Karaj A, Chirinos JA, Denney N, Grosso G, Fernando M, Chambers K, Demastus C, Reddy R, Langham M, Kumar D, Maynard H, Pourmussa B, Prenner SB, Cohen JB, Ischiropoulos H, Rickels MR, Poole DC, Church DD, Wolfe RR, Kelly DP, Putt M, Margulies KB, Zamani P Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure with Preserved Ejection Fraction , JACC Heart Fail, S2213-1779(25): 2025,00237-9


Selvaraj S; Kwee LC; Thompson EJ; He M; Hornik CP; Devore AD; Patel CB; Mentz RJ; Fudim M; Taylor L; Milosovic S; Hurdle M; Cade WT; Ilkayeva O; Muehlbauer MJ; Newgard CB; Kelly DP; Zamani P; Margulies KB; Shah SH Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF , J Am Coll Cardiol Basic Trans Science, 10(3): 2025,290-303


Zamani P, Shah SJ, Cohen JB, Zhao M, Yang W, Afable JL, Caturla M, Maynard H, Pourmussa B, Demastus C, Mohanty I, Miyake MM, Adusumalli S, Margulies KB, Prenner SB, Poole DC, Wilson N, Reddy R, Townsend RR, Ischiropoulos H, Cappola TP, Chirinos JA Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial , JAMA Cardiol., 10(3): 2025


Selvaraj S, Karaj A, Chirinos JA, Denney N, Fernando M, Chambers K, Demastus C, Langham M, Maynard H, Pourmussa B, Prenner SB, Cohen J, Ischiropoulos H, Rickels M, Church D, Wolfe R, Kelly DP, Putt ME, Margulies KB, Zamani P. FUEL UTILIZATION DURING EXERCISE WITH EXOGENOUS KETONES VERSUS PLACEBO IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: KETO-HFPEF , American College of Cardiology Annual Session, March 29-31, 2025; Chicago, IL.: 2025


Gan S; Azzo JD; Zhao L; Pourmussa B; Dib MJ; Salman O; Erten O; Ebert C; Richards AM; Javaheri A; Mann DL; Rietzschel E; Zamani P; van Empel V; Cappola TP, Chirinos JA Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations. , Circ Heart Fail, 18(2): 2025,e011728


Selvaraj S, He C, Thompson E, Hornik CP, Devore AD, Patel CB, Mentz RJ, Fudim M, Kwee LC, Taylor L, Milosovic S, Hurdle M, Cade W, Ilkayeva O, Muehlbauer M, Newgard C, Kelly DP, Zamani P, Margulies KB, Shah SH Metabolic and Pharmacokinetic Profiling of Ketone Ester by Background SGLT2 Inhibitor Therapy in Heart Failure with Reduced Ejection: A Phase I Clinical Trial , American Heart Association Scientific Sessions: 2024


Salman O, Zamani P, Zhao L, Dib MJ, Gan S, Azzo JD, Pourmussa B, Richards AM, Javaheri A, Mann DL, Rietzschel E, Zhao M, Wang Z, Ebert C, Liu L, Gunawardhana KL, Greenawalt D, Carayannopoulos L, Chang CP, van Empel V, Gogain J, Schafer PH, Gordon DA, Ramirez-Valle F, Cappola TP, Chirinos JA Prognostic Significance and Biologic Associations of senescence-associated secretory phenotype (SASP) Biomarkers in Heart Failure (HF) , J Am Heart Assoc, 13(17): 2024,e033675


Selvaraj S, Chirinos JA, Putt M, Karaj A, Prenner SB, Cohen JA, Denney N, Gross G, Fernando M, Chambers K, Demastus C, Langham M, Kumar D, Maynard H, Poumussa B, Poole DC, Church DC, Wolfe RR, Margulies KB, Zamani P Effects Of Exogenous Ketone Therapy On Exercise Capacity In Heart Failure With Preserved Ejection Fraction: KETO-HFpEF , Heart Failure Society of America Annual Session: 2024


Dib MJ; Azzo JD; Zhao L; Salman O; Gan S; De Buyzere ML; De Meyer T; Ebert C; Gunawardhana K; Liu L; Gordon D; Seiffert D; Ching-Pin C; Zamani P; Cohen JB; Pourmussa B; Kun S; Gill D; Burgess S; van Empel V; Richards AM; Dennis D; Javaheri A; Mann DL; Cappola TP; Rietzschel E; Chirinos JA Proteome-Wide Genetic Investigation of Large Artery Stiffness , JACC Basic Transl Sci, 9(10): 2024,1178-1191